Patents/Inventors

Susan M. Freier

San Diego, CAUS54 patents

38 Patents

US126180692026
Compounds and Methods for Reducing ATXN3 Expression
Ionis Pharmaceuticals, Inc.
0 cites
US126068262026
Modulation of Transthyretin Expression
Ionis Pharmaceuticals, Inc.
0 cites
US126009702026
Compositions for Modulating C9ORF72 Expression
Ionis Pharmaceuticals, Inc.
0 cites
US125954852026
Modulation of Prekallikrein (PKK) Expression
Ionis Pharmaceuticals, Inc.
0 cites
US125841282026
Compositions for Modulating Ataxin 2 Expression
Ionis Pharmaceuticals, Inc.
0 cites
US125096812025
Antisense Oligonucleotides Directed to Huntingtin
0 cites
US124801262025
Modulation of Dystrophia Myotonica-protein Kinase (DMPK) Expression
University Of Rochester
0 cites
US124091882025
Modulators of HSD17B13 Expression
Ionis Pharmaceuticals, Inc.
0 cites
US123502852025
Compounds and Methods for Reducing ATXN3 Expression
Ionis Pharmaceuticals, Inc.
0 cites
US123433572025
Compositions and Methods for Modulating MECP2 Expression
Ionis Pharmaceuticals, Inc.
0 cites
US122974312025
Modulation of Huntingtin Expression
Ionis Pharmaceuticals, Inc.
0 cites
US122813052025
Compounds and Methods for Reducing Prion Expression
Ionis Pharmaceuticals, Inc.
0 cites
US122410672025
Compounds and Methods for Reducing LRRK2 Expression
Ionis Pharmaceuticals, Inc.
0 cites
US121804792024
Compounds and Methods for Modulating ATXN1
Ionis Pharmaceuticals, Inc.
0 cites
US121687662024
Modulators of APOL1 Expression
ASTRAZENECA AB
0 cites
US121578902024
Modulators of MALAT1 Expression
Ionis Pharmaceuticals, Inc.
0 cites
US121520522024
Compounds and Methods for Reducing MECP2 Expression
Ionis Pharmaceuticals, Inc.
0 cites
US121104912024
Selective Reduction of Allelic Variants
Ionis Pharmaceuticals, Inc.
0 cites
US120916622024
Compositions for Modulating Tau Expression
Biogen MA Inc.
0 cites
US120438312024
Modulation of Alpha Synuclein Expression
Ionis Pharmaceuticals, Inc.
0 cites
US120425102024
Modulators of IRF4 Expression
Ionis Pharmaceuticals, Inc.
0 cites
US119818972024
Compounds and Methods for Modulation of Dystrophia Myotonica-protein Kinase (DMPK) Expression
Ionis Pharmaceuticals, Inc.
0 cites
US119268302024
Modulators of Complement Factor B
Ionis Pharmaceuticals, Inc.
0 cites
US119268252024
Compounds and Methods for Reducing ATXN2 Expression
Ionis Pharmaceuticals, Inc.
0 cites
US118734952024
Compounds and Methods for Reducing LRRK2 Expression
Ionis Pharmaceuticals, Inc.
0 cites
US118406862023
Modulation of Prekallikrein (PKK) Expression
Ionis Pharmaceuticals, Inc.
0 cites
US118346602023
Compositions for Modulating Ataxin 2 Expression
Ionis Pharmaceuticals, Inc.
0 cites
US117811432023
Modulators of PNPLA3 Expression
IONIS PHARMACEUTICALS, Inc.
0 cites
US117610002023
Compositions and Their Uses Directed to Huntingtin
IONIS PHARMACEUTICALS, Inc.
0 cites
US117448462023
0 cites
US117322652023
Compositions and Methods for Modulating Complement Factor B Expression
Ionis Pharmaceuticals, Inc.
0 cites
US117134622023
Modulation of GYS1 Expression
The Hospital For Sick Children
0 cites
US116347112023
Methods and Compositions for Modulating Apolipoprotein (a) Expression
Ionis Pharmaceuticals, Inc.
0 cites
US116334832023
Modulators of PCSK9 Expression
IONIS PHARMACEUTICALS, Inc.
0 cites
US115915952023
Compositions for Modulating Tau Expression
Biogen MA Inc.
0 cites
US115835482023
Compounds and Methods for Reducing ATXN3 Expression
Ionis Pharmaceuticals, Inc.
0 cites
US115662452023
Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
Ionis Pharmaceuticals, Inc.
0 cites
US115477182023
Modulators of FOXP3 Expression
Ionis Pharmaceuticals, Inc.
0 cites